FDA's drug and device review process: hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, February 6, 1992, Volume 4
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 1992 - Political Science - 178 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
advisory committee meeting Agency agency,s agenda aiaw Apnqs application Aprqs aq oq Arthritis asBasxp asked asor atqa audit Barton believe Burlington cells Center for Devices Center for Drugs Chairman clinical investigators clinical trial conduct consultant correct D-penicillamine DD SAN FRAN December DeCola Dermatology Dingell Director discussion disease Drug Administration drug application drug development Drug Evaluation Edelson effective Evaluation and Research FDA review FDA,s FDA's Food and Drug Freundlich Harter involved issues January January 17 letter months nvs aa participation patients Peck Phase III study photopheresis placebo protocol qeqq qqxw qsqq questions received record requested response rheumatoid arthritis rheumatologist Rook Rowland scheduled scientific skin severity score sponsor squaxqed staff study design subcommittee submitted sxqq sxxao tacrine Therakos therapy tion treatment University of Pennsylvania upns Weisman Wintroub Woodcock